These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38554421)
41. Gut microbiota and irritable bowel syndrome. Zhao Y; Zou DW J Dig Dis; 2023 May; 24(5):312-320. PubMed ID: 37458142 [TBL] [Abstract][Full Text] [Related]
42. Mucosa-Associated Microbiota in Patients with Irritable Bowel Syndrome: A Comparison of Subtypes. Matsumoto H; Shiotani A; Katsumata R; Fukushima S; Handa Y; Osawa M; Murao T; Handa O; Umegaki E; Inoue R; Naito Y Digestion; 2021; 102(1):49-56. PubMed ID: 33271532 [TBL] [Abstract][Full Text] [Related]
43. Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Liu Y; Zhang L; Wang X; Wang Z; Zhang J; Jiang R; Wang X; Wang K; Liu Z; Xia Z; Xu Z; Nie Y; Lv X; Wu X; Zhu H; Duan L Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1602-1611.e5. PubMed ID: 27266978 [TBL] [Abstract][Full Text] [Related]
44. Mucosal-Associated Microbiota Other Than Luminal Microbiota Has a Close Relationship With Diarrhea-Predominant Irritable Bowel Syndrome. Yang M; Hong G; Jin Y; Li Y; Li G; Hou X Front Cell Infect Microbiol; 2020; 10():515614. PubMed ID: 33224895 [TBL] [Abstract][Full Text] [Related]
45. An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila. Cruz-Aguliar RM; Wantia N; Clavel T; Vehreschild MJGT; Buch T; Bajbouj M; Haller D; Busch D; Schmid RM; Stein-Thoeringer CK Digestion; 2019; 100(2):127-138. PubMed ID: 30423561 [TBL] [Abstract][Full Text] [Related]
46. Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis. Wang B; Zhu S; Liu Z; Wei H; Zhang L; He M; Pei F; Zhang J; Sun Q; Duan L Genomics Proteomics Bioinformatics; 2020 Dec; 18(6):708-720. PubMed ID: 33607299 [TBL] [Abstract][Full Text] [Related]
47. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. Kurokawa S; Kishimoto T; Mizuno S; Masaoka T; Naganuma M; Liang KC; Kitazawa M; Nakashima M; Shindo C; Suda W; Hattori M; Kanai T; Mimura M J Affect Disord; 2018 Aug; 235():506-512. PubMed ID: 29684865 [TBL] [Abstract][Full Text] [Related]
48. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Zeber-Lubecka N; Kulecka M; Ambrozkiewicz F; Paziewska A; Goryca K; Karczmarski J; Rubel T; Wojtowicz W; Mlynarz P; Marczak L; Tomecki R; Mikula M; Ostrowski J Gut Microbes; 2016 Sep; 7(5):397-413. PubMed ID: 27662586 [TBL] [Abstract][Full Text] [Related]
49. Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review. Hou JJ; Wang X; Wang YM; Wang BM Crit Rev Microbiol; 2022 Nov; 48(6):696-713. PubMed ID: 34936854 [TBL] [Abstract][Full Text] [Related]
50. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. Bennet SMP; Böhn L; Störsrud S; Liljebo T; Collin L; Lindfors P; Törnblom H; Öhman L; Simrén M Gut; 2018 May; 67(5):872-881. PubMed ID: 28416515 [TBL] [Abstract][Full Text] [Related]
51. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. Tanaka Y; Yamashita R; Kawashima J; Mori H; Kurokawa K; Fukuda S; Gotoh Y; Nakamura K; Hayashi T; Kasahara Y; Sato Y; Fukudo S J Gastroenterol; 2022 Oct; 57(10):748-760. PubMed ID: 35908139 [TBL] [Abstract][Full Text] [Related]
52. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Tap J; Derrien M; Törnblom H; Brazeilles R; Cools-Portier S; Doré J; Störsrud S; Le Nevé B; Öhman L; Simrén M Gastroenterology; 2017 Jan; 152(1):111-123.e8. PubMed ID: 27725146 [TBL] [Abstract][Full Text] [Related]
53. Significant Differences in Gut Microbiota Between Irritable Bowel Syndrome with Diarrhea and Healthy Controls in Southwest China. Yao C; Li Y; Luo L; Xie F; Xiong Q; Li T; Yang C; Feng PM Dig Dis Sci; 2023 Jan; 68(1):106-127. PubMed ID: 35503487 [TBL] [Abstract][Full Text] [Related]
55. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. Krogius-Kurikka L; Lyra A; Malinen E; Aarnikunnas J; Tuimala J; Paulin L; Mäkivuokko H; Kajander K; Palva A BMC Gastroenterol; 2009 Dec; 9():95. PubMed ID: 20015409 [TBL] [Abstract][Full Text] [Related]
56. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. Fodor AA; Pimentel M; Chey WD; Lembo A; Golden PL; Israel RJ; Carroll IM Gut Microbes; 2019; 10(1):22-33. PubMed ID: 29708822 [TBL] [Abstract][Full Text] [Related]
57. Characterizing the gut microbiota in patients with chronic kidney disease. Hu X; Ouyang S; Xie Y; Gong Z; Du J Postgrad Med; 2020 Aug; 132(6):495-505. PubMed ID: 32241215 [No Abstract] [Full Text] [Related]